A Common Polymorphism in the Complement Factor H Gene Is Associated With Increased Risk of Myocardial Infarction
The Rotterdam Study
Isabella Kardys, MD*,
Caroline C.W. Klaver, MD, PhD*, ,
Dominiek D.G. Despriet, MD*, ,
Arthur A.B. Bergen, PhD¶,||,
André G. Uitterlinden, PhD ,
Albert Hofman, MD, PhD*,
Ben A. Oostra, PhD ,
Cornelia M. Van Duijn, PhD*,
Paulus T.V.M. de Jong, MD, PhD*,¶,# and
Jacqueline C.M. Witteman, PhD*,*
* Department of Epidemiology & Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands
Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
¶ Department of Ophthalmogenetics, Netherlands Ophthalmic Research Institute, Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands
|| Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands
# Department of Ophthalmology, Academic Medical Center, Amsterdam, the Netherlands

View larger version (24K):
[in a new window]
|
Figure 1 Flow chart describing study population. CFH = complement inhibitor factor H; DNA = deoxyribonucleic acid.
|
|

View larger version (18K):
[in a new window]
|
Figure 2 Age- and gender-adjusted event-free survival until incident myocardial infarction.
|
|

View larger version (48K):
[in a new window]
|
Figure 3 Age- and gender-adjusted hazard ratios for myocardial infarction according to Tyr402His genotype in subgroups, created according to median values for continuous variables. BMI = body mass index; CRP = C-reactive protein; HDL = high-density lipoprotein.
|
|
|